Benzinga | Jan 25, 2021 06:36AM EST

Sonnet BioTherapeutics Says it Successfully Completed a Non-Human Study of SON-080, Expects to Submit Investigational New Drug Application in 2H 2021

* No adverse effects observed at all doses tested

* Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent doses for initiating pilot clinical efficacy studies

* An IND submission for Chemotherapy Induced Peripheral Neuropathy is expected in the second half of 2021